Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지

Independent Data Monitoring Committees: Review of Current Guidelines

국내 및 해외의 임상시험 데이터모니터링위원회 지침의 현황

  • Lee, Bo Ram (College of Pharmacy, Chungbuk National University) ;
  • Lee, Kyung Eun (College of Pharmacy, Chungbuk National University)
  • Received : 2016.04.19
  • Accepted : 2016.06.15
  • Published : 2016.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: There has been on increasing emphasis on the importance of monitoring the safety of participants in a clinical trial to protect patients and maintain the integrity of the trial. The independent data monitoring committee (IDMC) has become common component of randomized clinical trials in recent years. Methods: It is important to consider the implications of different approaches that are being used in various countries. IDMC guidelines in Korea, US, and Europe were reviewed and compared to provide the objective, composition and operation of IDMC in detail. Results: IDMC is a group of experts in related subject are as who perform interim data monitoring to make a recommendation to the sponsor or organizer regarding appropriateness of trial continuation and the need for modifications of the trial. Independence of IDMC is preferred in order to minimize influence of factors unrelated to scientific, medical and ethical considerations that should underlie decision-making. Conclusion: IDMC has become an increasingly important component of clinical trials in recent years. Practical operating procedures need to be developed considering the future regulatory status of data monitoring committees.

Keywords

References

  1. Schulz KF, Chalmers I, Hayes RJ, et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-412. https://doi.org/10.1001/jama.1995.03520290060030
  2. International Conference on Harmonization. E6: good clinical practice-GCP. Available from: http://www.ich.org/products/guidelines/efficacy/efficacy-single/article/good-clinical-practice.html. Accessed March 5, 2016.
  3. National Institutes of Health. NIH policy for data and safety monitoring. Available from: https://grants.nih.gov/grants/guide/notice-files/not98-084.html. Accessed March 5, 2016.
  4. National Cancer Institute. NCI Cooperative Group Data Monitoring Committee Policy. Available from: http://ctep.cancer.gov/protocolDevelopment/default.htm. Accessed March 13, 2016.
  5. Radiation Therapy Oncology Group. Phase III Data Monitoring Committee. Available from: https://www.rtog.org/LinkClick.aspx?fileticket=R3fG2hYgdqE=&tabid=183. Accessed March 13, 2016.
  6. Korean Ministry of Food and Drug Safety. Guideline on Good Clinical Practice. Available from: https://drug.mfds.go.kr/Data/KO_DU/2010-0803173903_0.hwp. Accessed March 13, 2016.
  7. Korean Ministry of Food and Drug Safety. Guideline on establishment and operation of independent data monitoring committee. Available from: http://drug.mfds.go.kr/eBook/access/ecatalog.jsp?Dir=76&catimage=. Accessed February 26, 2016.
  8. US Food and Drug Administration. Guidance for Clinical Trial Sponsors on the Establishment and Operation of Clinical Trial Data Monitoring Committee 2001; Available from: http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm127073.pdf. Accessed February 26, 2016.
  9. World Health Organization. Special Program for Research and Training in Tropical Diseases (TDR). Operational Guidelines for the Establishment and Functioning of Data and Safety Monitoring Boards. Available from: http://osp.od.nih.gov/sites/default/files/resources/operational-guidelines.pdf. Accessed February 26, 2016.
  10. European Medicine Agency. Guideline on Data Monitoring Committees. Available from: http://osp.od.nih.gov/sites/default/files/resources/WC500003635.pdf. Accessed March 1, 2016.